Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world registry of edaravone sublingual tablets in ALS
ChiCTR2400091187Phase 4Recruiting
- Sponsor
- Biosnwill
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of edaravone in amyotrophic lateral sclerosis (ALS), sponsored by Biosnwill. Primary endpoint: Change in ALSFRS-R score. Started Oct 2024; status: recruiting.
02
Drugs
edaravone
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on ChiCTR2400091187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091187.